Comment from Canary Cure Therapeutics
AnonymousSupportBusiness
Summary: Canary Cure Therapeutics supports the proposed Plausible Mechanism Framework (PMF) and commends the Agency for clarifying its scope. They argue that the final guidance should explicitly include multi-payload RNA biologics, provide specific operational standards for external-control evidentiary packages, and acknowledge causative-protein measurements as valid biomarkers for loss-of-function mutations.
Executive Summary (please see attached document)
Canary Cure Therapeutics respectfully submits these comments on the February 23, 2026 draft guidance on the Plausible Mechanism Framework (PMF), Docket FDA-2026-D-1256. We commend the Agency for formalizing the principles articulated by Dr. Teresa Buracchio in her April 15, 2026 interview with Fierce Biotech: that the PMF is a set of reviewable principles rather than a pathway, and that it is not confined to n-of-1 ASOs. Those clarifications create important regulatory space for ultra-rare monogenic diseases that are well-defined biochemically but too small to power a classical randomized pivotal trial.
We offer three comments and one illustrative case study. In summary:
1.The final guidance should explicitly affirm that the PMF's principles extend to multi-payload RNA biologics (siRNA + mRNA co-delivered in a single LNP), not only single-modality ASOs, AAV, or base editors.
2.The external-control evidentiary standard should be operationalized with pre-specified elements — including contemporaneous registry data, placebo-response adjustment, and independent data monitoring — drawing explicit lessons from the uniQure AMT-130 precedent.
3.The PMF's "reviewable principles" concept should accommodate biomarker anchoring at the causative-protein level (e.g., serum leptin for LEP-deficient obesity), consistent with the January 2026 BEAM-302 accelerated-approval precedent.
4.Case study: CCT-987, a CB1R-silencing siRNA plus leptin mRNA co-formulated in an adipocyte-targeted LNP for congenital leptin deficiency (CLD), is offered as an archetypal PMF candidate to help the Agency stress-test the framework language against a multi-payload RNA construct.